Quest Diagnostics
View test Contact us

Powering affordable care

through early identification of type 2 diabetes risk

Request Information
Early identification of Type 2 Diabetes Risk

Insulin resistance can be a first step in the progression to cardiometabolic disease. If diagnosis is delayed until the patient exhibits hyperglycemia or other symptoms, progression to prediabetes or type 2 diabetes (T2D) may have already occurred.1,2

40% of young American
adults have insulin resistance3
8.7% of the US population has been diagnosed with diabetes5
96 million US adults —over a third—have prediabetes4 More than 8 in 10 of them don't know it4

Cardiometabolic diseases are conditions of associated risk

  • Patients with T2D have a 2-3x higher risk of fatal coronary heart disease6
  • Nearly 40% of people who have diabetes also have chronic kidney disease (CKD)7
  • More than 70% of those who have T2D have nonalcoholic fatty liver disease (NAFLD)8

Get ahead of insulin resistance

Use this form to request information and resources from your Quest representative.

*Required fields

Request Information

Insulin Resistance (IR) Panel with Score

Patients can have normal glucose and HbA1c, but may have IR that puts them at risk of developing prediabetes and diabetes.3 Fasting insulin and C-peptide measurements detect IR and possible risk of prediabetes or diabetes 10 years or more before T2D is diagnosed. For your patients with risk factors for diabetes, detecting IR now can help you work together to achieve better outcomes.

Identify IR 10 years or more before T2D is diagnosed1

Structured lifestyle changes can decrease risk by 58%9

Utilize enhanced reporting for effective patient counseling

Test Name Cardio IQ® Insulin Resistance Panel with Score
Test Description The determination of insulin in serum is primarily used for the diagnosis of glycemic disorders in diabetic and pre-diabetic patients in the assessment of insulin resistant syndromes.
Test Code 36509
CPT 83525, 84681
Preferred Specimen 0.5 mL serum
Transport Tempature Refrigerated (cold packs)
Specimen Stability Room tempature: 24 hours; Refrigerated: 28 days; Frozen: 28 days

All panel components can be ordered separately: Insulin, Intact, LC/MS/MS (test code 93103); C-Peptide (test code 372); IR Score (test code 36509) Quest Diagnostics offers a complete selection of cardiometabolic and endocrine tests, including data-based insights and proprietary cardiometabolic markers. Complete information at Cardiometabolic disease | Quest Diagnostics

Selected tests availables

  Test Code
Cardio IQ® Glucose 91947
Cardio IQ® Hemoglobin A1c 91732
Metabolic Risk Panel
Includes: Cardio IQ® Cholesterol, Total(91717); Cardio IQ® HDL Cholesterol(91719); Cardio IQ® Triglycerides(91718); Cardio IQ® Non-HDL and Calculated Components (91716); Cardio IQ® Apolipoprotein B (91726); Cardio IQ® Hemoglobin A1c (91732); Insulin, Intact, LC/MS/MS (93103); C-Peptide (372), LC/MS/MS and IR Score (36509) 		39447
Cardio IQ® Insulin Resistance Panel with Score
Includes: Insulin, Intact, LC/MS/MS (93103); C-Peptide (372); IR Score (36509) 		36509
Insulin, Intact, LC/MS/MS 93103
C-Peptide 372

Reverse course by revealing hidden risks

Quest Diagnostics is committed to supporting clinicians in the early identification of type 2 diabetes and other conditions associated with IR through the Cardio IQ® Insulin Resistance Panel with Score.

Learn More

Request more information from your Quest representative

Request Information

New customer? Sign up to be contacted by your local Quest representative

Sign Up

References: 1. Holman RR. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract. 1998;40 Suppl:S21-S25. doi:10.1016/s0168-8227(98)00038-2 2. Reaven GM. The insulin resistance syndrome. Curr Atheroscler Rep. 2003;5(5):364-371. doi:10.1007/s11883-003-0007-0 3. Vibhu Parcha, Brittain Heindl, Rajat Kalra, et al., Insulin Resistance and Cardiometabolic Risk Profile Among Nondiabetic American Young Adults: Insights From NHANES, The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 1, January 2022, Pages e25–e37,https://doi.org/10.1210/clinem/dgab645 4. Centers for Disease Control and Prevention. Prevalence of Diagnosed Diabetes. https://www.cdc.gov/diabetes/data/statistics-report/diagnosed-diabetes.html#:~:text=28.7%20million%20people%20of%20all%20ages%E2%80%94or%208.7%25%20of,diabetes. %20This%20includes%20244%2C000%20with%20type%201%20diabetes. December 17, 2021. Accessed May 26, 2022. 5. Centers for Disease Control and Prevention. Diabetes Fast Facts. https://www.cdc.gov/diabetes/basics/quick-facts.html. December 17, 2021. Accessed March 3, 2022. 6. Huxley R et al. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332(7533):73-78 7. Pavkov ME et al. Kidney disease in diabetes. In: Cowie CC, Casagrande SS, Menke A, et al, eds. Diabetes in America.3rd edition. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases (US); 2018.Accessed June 11, 2021. https://www.ncbi.nlm.nih.gov/books/NBK568002 8. Portillo-Sanchez P et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab. 2015;100:2231-2238. 9. Centers for Disease Control and Prevention. About the National DPP. https://www.cdc.gov/diabetes/prevention/about.htm April 14, 2022. Accessed September 23, 2022.

The CPT codes provided are based on American Medical Association guidelines and are for informational purposes only, CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
Image content features models and is intended for illustrative purposes only.